Aastrom hangs onto its Nasdaq listing
This article was originally published in Scrip
Executive Summary
Aastrom Biosciences has until October 1st to regain compliance with Nasdaq listing requirements or face being delisted from the stock exchange. Nasdaq granted the company a stay of execution after its share price failed to trade at $1 for 10 consecutive days.